ProCE Banner Activity

Subgroup Analysis of Patients With Refractory SCLC From a Phase I/II Trial Evaluating the Novel ADC Ifinatamab Deruxtecan

Conference Coverage

Among 21 efficacy-evaluable patients with heavily pretreated SCLC, the novel antibody–drug conjugate ifinatamab deruxtecan demonstrated an ORR of 52% and a median duration of response of 5.9 months.

Released: September 13, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences Inc., and Regeneron Pharmaceuticals, Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Regeneron Pharmaceuticals, Inc